Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

recordati ireland ltd. - enalapril; lerkanidipin - filmsko obložena tableta - enalapril 15,29 mg / 1 tableta  lerkanidipin9,44 mg / 1 tableta; lerkanidipin 9,44 mg / 1 tableta - enalapril in lerkanidipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

recordati ireland ltd. - enalapril; lerkanidipin - filmsko obložena tableta - enalapril 15,29 mg / 1 tableta  lerkanidipin18,88 mg / 1 tableta; lerkanidipin 18,88 mg / 1 tableta - enalapril in lerkanidipin

Evropska unija - slovenščina - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - akutni koronarni sindrom - antitrombotična sredstva - angiox je indiciran kot antikoagulant pri odraslih bolnikih s perkutano koronarnim posegom (pci), vključno z bolniki z miokardnim infarktom elevacije st (stemi), ki se podvrže primarni pci. angiox je prikazano tudi za zdravljenje odraslih bolnikov z nestabilno angino pektoris / non-st-segmenta,-dvig miokardni infarkt (ua / nstemi) načrtovana za nujne ali zgodnje intervencije. angiox je treba dajati z aspirinom in clopidogrel.

Evropska unija - slovenščina - EMA (European Medicines Agency)

n.v. organon - ganirelix - reproductive techniques, assisted; ovulation induction; infertility, female - hipofize in hipotalamični hormoni in analogi - preprečevanje prezgodnje skokovitega luteinising hormona pri ženskah v postopku pod nadzorom hiperstimulacije jajčnikov za reprodukciji tehnike. v kliničnih študijah, orgalutran je bila uporabljena s rekombinantne človeške folikle stimulirajočega hormona ali corifollitropin alfa, trajno folikle stimulans.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotična sredstva - xarelto, co-daje z acetilsalicilne kisline (asa) samostojno ali s asa plus clopidogrel ali ticlopidine, je označen za preprečevanje atherothrombotic dogodkov pri odraslih bolnikih po akutni koronarni sindrom (acs) s povišano srčno biomarkerje. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

l. molteni & c. dei fratelli alitti società di esercizio s.p.a. - buprenorfin hidroklorid - opioidne motnje - druga zdravila na živčnem sistemu - sixmo je primerna za nadomestno zdravljenje odvisnosti od opioidov v klinično stabilno odraslih bolnikih, ki ne zahtevajo več kot 8 mg/dan sublingual buprenorfin, v okviru medicinske, socialne in psihološke obravnave.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biomarin international limited - pegvaliase - fenilketonurije - drugi proizvodi prebavnega trakta in metabolizma - palynziq je indiciran za zdravljenje bolnikov z phenylketonuria (pku), starih 16 let in več, ki imajo neustrezne krvi fenilalanin nadzor (kri fenilalanin ravni večji od 600 micromol/l) kljub pred upravljanje z razpoložljive možnosti zdravljenja.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotična sredstva - preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 za haemodynamically nestabilno pe bolnikov). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 in 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek za peroralno suspenzijo - hranila brez fenilalanina

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek za peroralno suspenzijo - hranila brez fenilalanina